Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

MAIA

MAIA Biotechnology Inc

Apr 18 • 04:00PM ET

1.96

Dollar change -0.02
Percentage change -1.01	%

Healthcare • Biotechnology • USA • AMEX

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.45	Insider Own	24.79%	Shs Outstand	16.99M	Perf Week	-19.34%
Market Cap	39.20M	Forward P/E	-	EPS next Y	-	Insider Trans	10.05%	Shs Float	15.04M	Perf Month	15.98%
Income	-19.77M	PEG	-	EPS next Q	-0.39	Inst Own	3.96%	Short Float	5.62%	Perf Quarter	55.56%
Sales	0.00M	P/S	-	EPS this Y	-6.02%	Inst Trans	114.80%	Short Ratio	2.52	Perf Half Y	-12.89%
Book/sh	0.03	P/B	69.73	EPS next Y	-	ROA	-201.88%	Short Interest	0.85M	Perf Year	-47.87%
Cash/sh	0.36	P/C	5.48	EPS next 5Y	-	ROE	-440.12%	52W Range	0.82 - 4.25	Perf YTD	67.52%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-25.01%	ROI	-4140.83%	52W High	-53.88%	Beta	0.51
Dividend TTM	-	Quick Ratio	1.53	Sales past 5Y	0.00%	Gross Margin	-	52W Low	139.02%	ATR (14)	0.23
Dividend Ex-Date	-	Current Ratio	1.53	EPS Y/Y TTM	10.84%	Oper. Margin	0.00%	RSI (14)	46.39	Volatility	10.19% 14.15%
Employees	13	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	14.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	2.67%	Payout	-	Rel Volume	0.20	Prev Close	1.98
Sales Surprise	-	EPS Surprise	6.49%	Sales Q/Q	-	Earnings	Nov 07 BMO	Avg Volume	335.44K	Price	1.96
SMA20	-13.48%	SMA50	10.84%	SMA200	12.72%	Trades		Volume	67,590	Change	-1.01%

Apr-05-24 08:01AM	MAIA Biotechnology to Present at Two Investor Conferences in April 2024 (Business Wire) +6.82%
Mar-28-24 03:00PM	MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero (Business Wire) -11.29%
Mar-26-24 03:00PM	MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement (Business Wire)
08:01AM	MAIA Biotechnology Announces $1.33 Million Private Placement (Business Wire)
Mar-22-24 03:00PM	MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement (Business Wire) +8.76%
03:00PM	Loading…
Mar-21-24 03:00PM	MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board (Business Wire) +17.58%
Mar-16-24 01:49AM	Director Ngar Louie Acquires 170,940 Shares of MAIA Biotechnology Inc (MAIA) (GuruFocus.com)
Mar-07-24 09:45AM	MAIA Biotechnology to Participate in the 36th Annual ROTH Conference (Business Wire)
Mar-06-24 11:04AM	MAIA Biotechnology and Nationwide Childrens Hospital Announce Presentation of THIOs Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting (Business Wire)
08:48AM	MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients (Business Wire)
Mar-05-24 08:45AM	MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders (Business Wire)
Feb-27-24 10:30AM	MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor (GlobeNewswire)
Feb-22-24 10:30AM	MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer (GlobeNewswire)
Feb-07-24 08:01AM	MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer (Business Wire)
Jan-24-24 07:15AM	MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds (Business Wire)
09:00AM	Loading…
Jan-17-24 09:00AM	MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024 (Business Wire) +20.33%
Jan-05-24 08:00AM	MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024 (Business Wire) +26.89%
Dec-19-23 07:00AM	MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer (Business Wire)
Dec-01-23 09:55AM	Bears are Losing Control Over MAIA Biotechnology, Inc. (MAIA), Here's Why It's a 'Buy' Now (Zacks)
Nov-17-23 03:52PM	MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering (Business Wire) -13.57%
09:00AM	MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer (ACCESSWIRE)
Nov-15-23 09:35AM	MAIA Biotechnology Announces $4 Million Registered Direct Offering (Business Wire) -24.73%
Nov-10-23 07:01AM	FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma (Business Wire)
Nov-07-23 09:01AM	MAIA Biotechnology Inc (MAIA) Reports Q3 2023 Financial Results and Progress in Anticancer ... (GuruFocus.com)
08:15AM	MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO (Business Wire)
Oct-31-23 09:00AM	MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer (ACCESSWIRE)
Oct-30-23 08:41AM	MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO (Business Wire) +5.82%
Oct-24-23 08:00AM	MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial (Business Wire)
Oct-19-23 08:35AM	MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023 (Business Wire)
Oct-17-23 09:00AM	MAIA Biotechnology's THIO Emerges As Potential Breakthrough In Pediatric Brain Cancer Therapy (ACCESSWIRE) -5.06%
08:01AM	Loading…
08:01AM	MAIA Biotechnology to Present Latest Findings for Second Generation THIO Program at Turkish Biochemical Societys International Biochemistry Congress 2023 (Business Wire)
Oct-12-23 09:20AM	MAIA Biotechnology Reveals New Data Showing THIOs Potent Anticancer Activity in Aggressive Pediatric Brain Cancer (Business Wire)
Oct-10-23 11:15AM	MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed Patients (Business Wire)
08:01AM	MAIA Biotechnology Announces Potent Anticancer Activity of THIO in Gliomas (Business Wire)
Oct-03-23 08:01AM	MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer (Business Wire) -7.48%
Sep-28-23 08:01AM	MAIA Biotechnology Announces Share Repurchase Program (Business Wire) +11.80%
Aug-21-23 09:55AM	MAIA Biotechnology, Inc. (MAIA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-15-23 10:20AM	Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Aug-08-23 08:00AM	MAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer (Business Wire)
Jul-11-23 08:00AM	MAIA Biotechnology Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer (Business Wire)
Jul-10-23 08:00AM	MAIA Biotechnology Reports Updates on Preliminary Survival Data for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer (Business Wire)
Jun-20-23 08:00AM	MAIA Biotechnology Announces Updates in Enrollment in Phase II Clinical Trial: THIO-101 Has Enrolled 29 Patients (Business Wire) -9.44%
Jun-07-23 08:00AM	MAIA Biotechnology Files Second Patent For New Telomere-Targeting Molecules Program (Business Wire)
May-08-23 08:00AM	MAIA Biotechnology Reports First Quarter 2023 Financial Results and Provides Corporate Update (Business Wire) -6.69%
May-01-23 06:45AM	Daily Vickers Top Buyers & Sellers for 05/01/2023 (Argus Research) +7.72%
Apr-27-23 04:10PM	MAIA Biotechnology, Inc. Announces Closing of Public Offering (Business Wire) +6.22%
Apr-24-23 09:06PM	MAIA Biotechnology, Inc. Announces Pricing of Public Offering (Business Wire) -7.80%
09:00AM	Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-20-23 08:00AM	MAIA Biotechnology Reports Preliminary Survival Data in Part A of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer (Business Wire)
Apr-18-23 08:52AM	MAIA Biotechnology Announces Excellent Efficacy of THIO in Liver Cancer Models (Business Wire)
Apr-12-23 02:17PM	MAIA Biotechnology (MAIA) Up on Positive Data From NSCLC Study (Zacks)
08:00AM	MAIA Biotechnology to Present at AACR Annual Meeting 2023 (Business Wire)
Apr-11-23 02:43PM	MAIA Biotechnology Touts Positive Data From Healthy Volunteer Study Of Potential Lung Cancer Candidate (Benzinga) +6.08%
08:00AM	MAIA Biotechnology Reports Positive Topline Data from Part A Safety Lead-In of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer (Business Wire)
Mar-24-23 04:30PM	MAIA Biotechnology Reports Full Year 2022 Financial Results and Provides Corporate Update (Business Wire) +15.31%
Mar-13-23 10:04AM	MAIA Biotechnology Announces No Exposure to Silicon Valley Bank (Business Wire) -5.25%
Mar-07-23 08:00AM	MAIA Biotechnology Doses First Patients in Europe in Ongoing Phase 2 Trial (THIO-101) Evaluating THIO for Non-Small Cell Lung Cancer Treatment (Business Wire)
Feb-13-23 12:07PM	ADDING MULTIMEDIA: MAIA Biotechnologys Telomere-targeting Agent THIO, in Combination With Checkpoint Inhibitor Immune Therapies Atezolizumab (anti-PD-L1) or Pembrolizumab (anti-PD-1), Demonstrated Significantly Greater Tumor Inhibition (Business Wire)
Jan-17-23 10:00AM	Sidoti's January Micro-Cap Conference (ACCESSWIRE)
08:00AM	MAIA Biotechnology Advances New Telomere-Targeting Molecule Program (Business Wire)
Jan-05-23 08:00AM	MAIA Biotechnology to Participate in Four Upcoming Investor Conferences (Business Wire)
Dec-20-22 08:00AM	MAIA Biotechnology Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer (Business Wire)
Dec-13-22 08:00AM	MAIA Biotechnology Expands Phase 2 THIO-101 Trial to Europe (Business Wire)
Dec-12-22 08:00AM	Diamond Equity Research Initiates Coverage on MAIA Biotechnology, Inc. (NYSE: MAIA) (GlobeNewswire) -5.71%
Nov-22-22 08:00AM	MAIA Biotechnology Announces Establishment of Rule 10b5-1 Trading Plan (Business Wire)
Nov-15-22 08:00AM	MAIA Biotechnology Presents Preclinical Data at SITC Annual Meeting Validating Efficacy of THIO in Treating Hepatocellular Carcinoma (Business Wire)
Nov-09-22 04:15PM	MAIA Biotechnology Reports Third Quarter 2022 Financial Results and Provides Corporate Update (Business Wire)
Nov-08-22 03:40PM	Sidoti's November Micro-Cap Virtual Conference (ACCESSWIRE) -5.26%
Oct-12-22 07:30AM	MAIA Biotechnology: Invitation to The ThinkEquity Conference (Newsfile)
Oct-06-22 08:00AM	MAIA Biotechnology to Participate in ThinkEquity Conference (Business Wire) +6.42%
Oct-04-22 07:30AM	UPDATE - Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on October 4, 2022 (GlobeNewswire)
Sep-30-22 09:00AM	Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on October 4, 2022 (GlobeNewswire)
Sep-29-22 09:01AM	MAIA Biotechnology to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (Business Wire)
Sep-08-22 08:00AM	MAIA Biotechnology to Participate in H.C. Wainwright 24th Annual Global Investment Conference (Business Wire)
Sep-06-22 08:00AM	MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022 (Business Wire)
Aug-30-22 11:07AM	MAIA Biotechnology to Present Anticancer THIO Platform at XIV International Round Table on Nucleosides, Nucleotides, and Nucleic Acids (Business Wire) +8.36%
Aug-22-22 08:00AM	MAIA Biotechnology Reports Second Quarter 2022 Financial Results and Provides Corporate Update (Business Wire) +6.33%
Aug-02-22 08:00AM	MAIA Biotechnology Receives FDA Orphan Drug Designation for THIO for the Treatment of Small-Cell Lung Cancer (SCLC) (Business Wire) -16.79%
Aug-01-22 03:30PM	MAIA Biotechnology Announces Closing of Initial Public Offering (Business Wire) +34.48%
Jul-27-22 07:52PM	MAIA Biotechnology Announces Pricing of Initial Public Offering (Business Wire)

MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Smith Stan	Director	Mar 14 '24	Buy	1.17	170,940	200,000	857,568	Mar 15 07:11 PM
Louie Ngar Yee	Director	Mar 14 '24	Buy	1.17	170,940	200,000	1,147,524	Mar 15 07:09 PM
Luput Cristian	Director	Mar 14 '24	Buy	1.17	69,282	81,060	367,350	Mar 15 07:08 PM
CHAOUKI STEVEN M	Director	Mar 14 '24	Buy	1.17	34,641	40,530	88,891	Mar 18 05:34 PM
Guerrero Ramiro	Director	Mar 14 '24	Buy	1.17	6,928	8,106	319,600	Mar 15 07:04 PM
Guerrero Ramiro	Director	May 18 '23	Buy	2.47	1,200	2,964	312,672	May 22 06:49 AM
Luput Cristian	Director	May 15 '23	Buy	2.63	3,000	7,890	298,068	May 17 06:55 AM
Vitoc Vlad	Chief Executive Officer	Apr 28 '23	Buy	2.50	4,000	10,000	809,121	May 01 06:30 AM
Smith Stan	Director	Apr 27 '23	Buy	2.25	133,300	299,925	686,628	Apr 28 06:46 AM
Louie Ngar Yee	Director	Apr 27 '23	Buy	2.25	48,000	108,000	976,584	Apr 28 06:49 AM
Guerrero Ramiro	Director	Apr 27 '23	Buy	2.25	8,500	19,125	311,472	Apr 28 06:50 AM
MCGUIRE JOSEPH F	Chief Financial Officer	Apr 27 '23	Buy	2.25	4,400	9,900	9,400	Apr 28 06:52 AM
Smith Stan	Director	Apr 20 '23	Buy	3.74	10,000	37,400	553,328	Apr 21 07:53 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MAIA

MAIA Biotechnology Inc

Upgrade your FINVIZ experience